Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986253 + nivolumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986253 + nivolumab + ipilimumab is an experimental combination immunotherapy regimen for advanced cancers. BMS-986253 is a fully human IgG1κ monoclonal antibody that targets and binds free interleukin-8 (IL-8), inhibiting its activity and thus reducing tumor-promoting inflammation and myeloid-derived suppressor cell recruitment. Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor, and ipilimumab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor; both enhance T-cell mediated antitumor immune responses. The triplet aims to improve clinical outcomes in advanced cancers, particularly in patients resistant to prior checkpoint inhibitor therapy. The combination is being studied in Phase 1 and 2 clinical trials for unresectable or metastatic solid tumors, including melanoma and other advanced cancers[1][3][4][7].
- Other names
- Anti-IL-8 monoclonal antibody + nivolumab + ipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IL8 (C-X-C Motif Chemokine Ligand 8)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BMS-986253 + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986253 + nivolumab + ipilimumab.